---
document_datetime: 2024-06-07 14:22:49
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lamivudine-teva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: lamivudine-teva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.2388277
conversion_datetime: 2025-12-22 21:44:02.223177
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Lamivudine Teva

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0026              | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 06/06/2024                          |                                             | SmPC and PL                      |           |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IB/0025/G   | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by   | 10/10/2022   | 15/11/2022   | SmPC, Annex II, Labelling and PL   | the MAH   |
|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|-----------|
| IG/1508     | A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 23/05/2022   | n/a          |                                    |           |
| IB/0023/G   | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 22/12/2021   | 15/11/2022   | SmPC and PL                        |           |

<div style=\"page-break-after: always\"></div>

|         | of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                          |            |            |                        | product - Implementation   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------|
| N/0022  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                           | 11/10/2021 | 15/11/2022 | PL                     |                            |
|         | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer | 06/07/2021 | n/a        |                        | IA/0021/G                  |
| IA/0020 | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                              | 09/02/2021 | 04/06/2021 | Annex II and PL        |                            |
| IB/0019 | B.II.e.1.b.1 - Change in immediate packaging of the finished product - Change in type/addition of a new container - Solid, semi-solid and non-sterile liquid pharmaceutical forms                                                                                                                                                                                                                                                          | 03/06/2020 | 04/06/2021 | SmPC, Labelling and PL |                            |

<div style=\"page-break-after: always\"></div>

| IA/0018   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                  | 11/12/2019   | n/a        |                                  |             |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----------------------------------|-------------|
| IAIN/0017 | B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition)                                                                                                                                                                                                                            | 11/02/2019   | n/a        |                                  |             |
| IA/0016/G | application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer | 24/10/2018   | n/a        |                                  | This was an |
| IB/0015   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                   | 18/05/2018   | 11/04/2019 | SmPC and PL                      |             |
| IB/0014   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                                                                                                                 | 03/08/2016   | 23/02/2017 | SmPC, Annex II, Labelling and PL |             |

<div style=\"page-break-after: always\"></div>

| IA/0013   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 29/03/2016   | 23/02/2017   | Annex II and PL     |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------------|
| II/0012/G | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.III.1.a.3 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from a new manufacturer (replacement or addition) B.III.2.z - Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - Other variation | 17/03/2016   | n/a          |                     |
| T/0011    | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 05/11/2014   | 16/12/2014   | SmPC, Labelling and |

<div style=\"page-break-after: always\"></div>

|             |                                                                                                                                                                                                                                                              |            |            | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R/0009      | Renewal of the marketing authorisation.                                                                                                                                                                                                                      | 24/07/2014 | 09/09/2014 | SmPC, Annex II, Labelling and PL | Based on the review of the available information and on the basis of a re-evaluation of the benefit risk balance, the CHMP is of the opinion that the quality, safety and efficacy of this medicinal product continues to be adequately and sufficiently demonstrated and therefore considered that the benefit risk profile of Lamivudine Teva continues to be favourable. The CHMP is of the opinion that the renewal can be granted with unlimited validity. |
| IAIN/0010   | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                       | 09/06/2014 | 09/09/2014 | Annex II and PL                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IB/0008     | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 10/02/2014 | 09/09/2014 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IAIN/0007   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                               | 31/05/2013 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| IAIN/0006/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished                                         | 13/04/2012 | 31/05/2012 | Annex II and PL                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | product, including quality control sites (excluding manufacturer for batch release) B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                       | site   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------|
| IB/0005/G | This was an application for a group of variations. Lamivudine Teva PI is being updated to reflect changes introduced during Zeffix renewal. The MAH also takes this opportunity to correct the text in sections 4.4 and 5.1 of the SmPC and section 1, 2 and 3 of the PL of Lamivudine Teva to bring it in line with the reference. These additional changes have been highlighted in yellow in the present & proposed table for better clarification. Sections 4.2, 4.4, 4.6 and 5.1 of the SmPC were updated as a response to the commitments made by the MAH as part of Zeffix licence renewal. The PL was revised accordingly. Major changes affected section 4.1 and 4.2 in light of the emergence of new data, which have questioned the appropriateness of lamivudine as first line therapy for CHB due to its high risk of resistance. As a consequence the indication was restricted and the availability of other antiviral agents with a better resistance profile highlighted. The need for combination therapy in patients with decompensated liver disease was also introduced. Section 4.6 was updated to reflect the complexity of the benefit/risk assessment of lamivudine treatment in breast | 11/11/2011 | 31/05/2012 | SmPC, Annex II and PL |        |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| Section 5.1 was updated frequency of meergence impact on the treatment affected section 4.4 and Furthermore the complete decompensated liver disease PI for Lamivudine Teva The MAH requested to update SmPC to improve clarity exacerbation of hepatitis, agents for CHB, and section with regards to the frequency on the SmPC Guideline rev.2 originator. The PL has been Section 4.4 of the SmPC improve clarity around the hepatitis, in line with other CHB. The approved text \" differentiate information C.I.2.a - Change in the SPC, generic/hybrid/biosimilar assessment of the same product - Implementation new additional data are submitted C.I.6.b - Change(s) to therapeutic Deletion of a therapeutic C.I.2.a - Change in the SPC, generic/hybrid/biosimilar assessment of the same product - Implementation   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| II/0003/G   | This was an application for a group of variations. To register an additional manufacturing process and to change the test procedure for the active substance lamivudine. B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate   | 17/02/2011   | 02/03/2011   |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|
| IA/0001     | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 22/12/2009   | n/a          |